Vertex Pharmaceuticals Inc. (VRTX)

177.72
NASDAQ : Health Technology
Prev Close 176.09
Day Low/High 177.50 / 180.05
52 Wk Low/High 151.80 / 195.81
Avg Volume 1.17M
Exchange NASDAQ
Shares Outstanding 257.04M
Market Cap 45.26B
EPS 8.20
P/E Ratio 20.62
Div & Yield N.A. (N.A)

Latest News

2 Trading Opportunities in Health Care

2 Trading Opportunities in Health Care

The potential of these setups on the weekly chart is rather good.

Trying the Long Side of Vertex's Stock Again

Trying the Long Side of Vertex's Stock Again

After pharmaceutical company breaks out, charts suggest now is the time to go back in.

Cramer: 2017 Was a Year of Resurrection and Revival

Cramer: 2017 Was a Year of Resurrection and Revival

Look no further than the top 10 winners in the S&P 500 and you will see just what I mean.

Cramer: Trump Doesn't Deserve All the Credit for Stock Rally

Cramer: Trump Doesn't Deserve All the Credit for Stock Rally

Of stocks seeing the biggest gains since the presidential election, only a few owe their success to Trump.

Vertex Pharmaceuticals Could Be Headed Higher Once Again

Vertex Pharmaceuticals Could Be Headed Higher Once Again

Trade from the long side, but have a sell stop below $149 in case of a reversal.

Vertex Pharmaceuticals: Looking East, West and to the Quants

Vertex Pharmaceuticals: Looking East, West and to the Quants

Let's examine VRTX's sharp decline today.

Another Day - Another Busy Slate of Earnings

Another Day - Another Busy Slate of Earnings

Ford Motor Co. leads a list of notable earnings reports being released throughout the day on Wednesday

Closing Bell: Vertex Pharmaceuticals Up on String of Upgrades; Records for Wall Street

Closing Bell: Vertex Pharmaceuticals Up on String of Upgrades; Records for Wall Street

The Nasdaq and S&P 500 ended at records for the second day in a row.

Cramer: There Are Powerful Themes in Several Bull Markets

Cramer: There Are Powerful Themes in Several Bull Markets

It's a wonder to me how split this market really is.

Takeaways and Observations: Market Reversal

"The rally in the face of today's data (detailed by Peter Boockvar in the previous post) tells me how much machines and algos dominate trading: a mild winter goosed construction jobs service job data is so-so ISM services has just given back the ent...

Cramer: Stay the Course, but Keep Cash Handy

Cramer: Stay the Course, but Keep Cash Handy

It's pretty normal to have profit-taking after such a strong first quarter.

Closing Bell: Barclays Bets on Alphabet Growth; Dow Falls, S&P 500 and Nasdaq Rise

Closing Bell: Barclays Bets on Alphabet Growth; Dow Falls, S&P 500 and Nasdaq Rise

A rally in crude oil gave rise to the energy sector in a mixed day of trading.

Vertex Pharmaceuticals Reaches Upside Price Target

Vertex Pharmaceuticals Reaches Upside Price Target

Base building pays off.

Vertex upgraded at BMO

Vertex upgraded at JMP

What You Must Know About Cystic Fibrosis Drug CTP-656

What You Must Know About Cystic Fibrosis Drug CTP-656

Acquiring CTP-656 from Concert Pharmaceuticals will only cost Vertex around $250 million.

Activist Investors Shake Up the Boards at Tiffany & Bristol-Myers Squibb

Activist Investors Shake Up the Boards at Tiffany & Bristol-Myers Squibb

Jana Partners are placing three members on Tiffany's board.

Vertex Pharmaceuticals to Rely on Acquisitions to Diversify Its Business

Vertex Pharmaceuticals to Rely on Acquisitions to Diversify Its Business

Vertex Pharmaceuticals will be weighing future acquisitions and partnerships to broaden is focus beyond cystic fibrosis.

Vertex Pharmaceuticals Sees Sales of Cystic Fibrosis Drug Lower Than Expected

Vertex Pharmaceuticals Sees Sales of Cystic Fibrosis Drug Lower Than Expected

Vertex Pharmaceuticals provided new financial guidance for 2017 on Sunday.

Here's What to Look for at the J.P. Morgan Healthcare Conference

Here's What to Look for at the J.P. Morgan Healthcare Conference

The biggest annual event for biotech and pharma investors starts Monday with the kickoff of the J.P. Morgan Healthcare Conference in San Francisco.

Cramer: Reviewing S&P's Hit-and-Miss Parade

Cramer: Reviewing S&P's Hit-and-Miss Parade

Even among the losers, buys are scarce.

More Base Building Ahead for Vertex Pharmaceuticals

More Base Building Ahead for Vertex Pharmaceuticals

Buy signals have not lasted more than two months, so far.

Vertex downgraded at Barclays

Bullish and Bearish Chart Reversals

Bullish and Bearish Chart Reversals

What stocks have changed direction in the past week.

5 Health Care Stocks Set to Bounce

5 Health Care Stocks Set to Bounce

These stocks are down some 20% over the last 30 months and look ripe for a rise.

A 'Semi-Charmed' Kind of NXPI Call Spread

A 'Semi-Charmed' Kind of NXPI Call Spread

It might be best to make this a late-afternoon purchase.

Cramer: How Did the Stock Market Get So Unwieldy?

The answer is that new data came out.

Charts Say Vertex Could Recover

The rate of decline slowed into the base, just what chartists like to see.